Combining varenicline and nicotine lozenges with smartphone support to help people quit smoking
A Randomized Factorial Trial of Varenicline with Nicotine Lozenges and a Smartphone Medication Adherence Intervention to Promote Smoking Cessation
This study is looking at whether using a combination of a smoking cessation pill, nicotine lozenges, and a helpful smartphone app can make it easier for people to quit smoking compared to just taking the pill alone, and it’s designed for anyone who wants to stop smoking.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-11070610 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of combining varenicline, a medication for smoking cessation, with nicotine lozenges and a smartphone app designed to improve medication adherence. The study aims to determine if this combination can enhance the chances of quitting smoking compared to using varenicline alone. Participants will receive behavioral support through the app, which will help track their progress and provide reminders to take their medications. The research will involve a randomized trial to assess the outcomes of this combined approach.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are motivated to quit smoking and are willing to use a smartphone app for support.
Not a fit: Patients who are not interested in quitting smoking or who are under 21 years old may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve smoking cessation rates, leading to better health outcomes and reduced cancer risk for participants.
How similar studies have performed: Previous research has shown success with similar combination therapies for smoking cessation, although this specific approach has not been extensively tested.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Kendzor, Darla Elizabeth — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Kendzor, Darla Elizabeth
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.